MetLife (MET) Stock Forecast & Price Target

MetLife is positioned for attractive fundamental growth because its earnings are anchored by capital-light, high-ROE franchises, with Group Benefits and RIS contributing about 52% of 2025 adjusted earnings and benefiting from share gains, voluntary product penetration, and disciplined pricing. The company’s scale, broad product suite, and AI/data capabilities should support operating leverage and expense improvement, while RIS, Latin America, Asia, and MIM add diversified growth, fee income, and incremental optionality through structures like Chariot Re. With 2025 adjusted EPS up 10% and adjusted ROE at 16%, near the top of the 15-17% range, the business mix shift toward higher-multiple segments supports a stronger earnings and return profile.

MetLife is viewed negatively because its earnings remain highly exposed to macro and market swings, including lower long-term interest rates, widening credit concerns, weaker equity markets, and unfavorable FX or regulatory developments that can pressure investment income, reserve adequacy, and fee revenue. While Group Benefits and RIS together drive around 52% of 2025 adjusted earnings and the Asia segment contributes about 25%, the firm’s heavy reliance on Japan and other international businesses adds geopolitical and policy risk, while Latin America, EMEA, and investment management add further exposure to volatile regional conditions. Even with a relatively inexpensive valuation at 9.6x 2026E P/E and 8.8x 2027E P/E, competition, mortality normalization, and any reversal in alternative asset returns could limit margin stability and earnings quality.